Monthly Archives: 1 月 2023

SWEET: a single-sample network inference method for deciphering individual features in disease

林峻宇助理教授研究團隊發表研究成果於Brief Bioinform.



Recently, extracting inherent biological system information (e.g. cellular networks) from genome-wide expression profiles for developing personalized diagnostic and therapeutic strategies has become increasingly important. However, accurately constructing single-sample networks (SINs) to capture individual characteristics and heterogeneity in disease remains challenging. Here, we propose a sample-specific-weighted correlation network (SWEET) method to model SINs by integrating the genome-wide sample-to-sample correlation (i.e. sample weights) with the differential network between perturbed and aggregate networks. For a group of samples, the genome-wide sample weights can be assessed without prior knowledge of intrinsic subpopulations to address the network edge number bias caused by sample size differences. Compared with the state-of-the-art SIN inference methods, the SWEET SINs in 16 cancers more likely fit the scale-free property, display higher overlap with the human interactomes and perform better in identifying three types of cancer-related genes. Moreover, integrating SWEET SINs with a network proximity measure facilitates characterizing individual features and therapy in diseases, such as somatic mutation, mut-driver and essential genes. Biological experiments further validated two candidate repurposable drugs, albendazole for head and neck squamous cell carcinoma (HNSCC) and lung adenocarcinoma (LUAD) and encorafenib for HNSCC. By applying SWEET, we also identified two possible LUAD subtypes that exhibit distinct clinical features and molecular mechanisms. Overall, the SWEET method complements current SIN inference and analysis methods and presents a view of biological systems at the network level to offer numerous clues for further investigation and clinical translation in network medicine and precision medicine.

A flexible liposomal polymer complex as a platform of specific and regulable immune regulation For individual cancer immunotherapy

廖光文教授研究團隊發表研究成果於 J Exp Clin Cancer Res




The applicability and therapeutic efficacy of specific personalized immunotherapy for cancer patients is limited by the genetic diversity of the host or the tumor. Side-effects such as immune-related adverse events (IRAEs) derived from the administration of immunotherapy have also been observed. Therefore, regulatory immunotherapy is required for cancer patients and should be developed.


The cationic lipo-PEG-PEI complex (LPPC) can stably and irreplaceably adsorb various proteins on its surface without covalent linkage, and the bound proteins maintain their original functions. In this study, LPPC was developed as an immunoregulatory platform for personalized immunotherapy for tumors to address the barriers related to the heterogenetic characteristics of MHC molecules or tumor associated antigens (TAAs) in the patient population. Here, the immune-suppressive and highly metastatic melanoma, B16F10 cells were used to examine the effects of this platform. Adsorption of anti-CD3 antibodies, HLA-A2/peptide, or dendritic cells’ membrane proteins (MP) could flexibly provide pan-T-cell responses, specific Th1 responses, or specific Th1 and Th2 responses, depending on the host needs. Furthermore, with regulatory antibodies, the immuno-LPPC complex properly mediated immune responses by adsorbing positive or negative antibodies, such as anti-CD28 or anti-CTLA4 antibodies.


The results clearly showed that treatment with LPPC/MP/CD28 complexes activated specific Th1 and Th2 responses, including cytokine release, CTL and prevented T-cell apoptosis. Moreover, LPPC/MP/CD28 complexes could eliminate metastatic B16F10 melanoma cells in the lung more efficiently than LPPC/MP. Interestingly, the melanoma resistance of mice treated with LPPC/MP/CD28 complexes would be reversed to susceptible after administration with LPPC/MP/CTLA4 complexes. NGS data revealed that LPPC/MP/CD28 complexes could enhance the gene expression of cytokine and chemokine pathways to strengthen immune activation than LPPC/MP, and that LPPC/MP/CTLA4 could abolish the LPPC/MP complex-mediated gene expression back to un-treatment.


Overall, we proved a convenient and flexible immunotherapy platform for developing personalized cancer therapy.

國立陽明交通大學生物科技學院生物科技學系 徵 計畫助理1名

國立陽明交通大學生物科技學院生物科技學系 徵 計畫助理1名


一、 職稱:計畫助理

二、 工作項目: 

     (一) 生科院系所網頁維護。

     (二) 各項活動辦理。

     (三) 大學部相關事宜。

     (四) 其他交辦事項及臨時業務。

三、 公告期間:自112年1月18日至112年2月10日止。

四、 僱用期間:自奉核可後實際報到日起。

五、 待遇:依國立陽明交通大學計畫專任工作人員薪酬支給標準表敘薪(大學學歷36,570元/月起薪、碩士學歷41,040元/月起薪)。

六、 資格條件:

     (一) 學歷:大學(含) 畢業以上。

     (二) 專長、相關證照或經歷:

         1. 耐心細心、認真負責、積極主動、溝通能力良好、抗壓性高能獨立作業者。

         2. 具網頁管理、公關媒體素材、影片剪輯相關經驗尤佳。


(一) 不得與本校校長、擬進用之單位主管或計畫項下執行單位主管等具配偶或三親等以內之血親、姻親關係。

(二) 無性別平等教育法第27-1條不得聘任、任用、進用或運用之情形:



(三) 不具在學身分(在職專班除外)。

(四) 不具雙重國籍。

八、 上班時間:依本校相關規定辦理。

九、 上班地點:國立陽明交通大學光復校區及博愛校區或其他業務需要地點。

十、 其他:

(一) 特別休假:依勞動基準法辦理。

(二) 試用期:試用期3個月,試用期滿成績及格者,予以正式僱用;成績不及格者,停止僱用。

十一、 應徵方式:應徵者請備妥下列資料,並註明應徵職稱,於112年2月10日前Email至(電子郵件或郵寄至「300新竹市東區博愛街75號賢齊館325室_國立陽明交通大學生物科技學系收 郭小姐」(郵寄以郵戳為憑)。

(一) 最高學(經)歷。

(二) 證照專長、個人作品等證明文件影本。

(三) 個人自傳、履歷表(請以A4格式,內容應含自傳、服務及經驗說明、個人連絡方式及電子郵件)。

(四) 其他有利應徵之文件。



十二、如經通知面試須切結確實無性別平等教育法第27-1 條所訂不得聘任、任用、進用或運用之情事。




十四、洽詢:若有任何問題,請電洽(03)5712121轉56937 郭小姐。


     (一) 正取1名,另擇優備取至多3名。

     (二) 本次甄選結果如無適當人員,得予從缺。


Hierarchical ensembles of FeCo metal-organic frameworks reinforced nickel foam as an impedimetric sensor for detection of IL-1RA in human samples

王雲銘教授研究團隊發表研究成果於 Chemical Engineering Journal



Early surveillance of oral cancer demands utmost concern owing to its alarming prevalence in the modern world. An efficient electrochemical impedimetric immunosensor is fabricated based on bimetallic amino-functionalized FeCo metal–organic frameworks uniformly grown on porous nickel foam solid supports (FeCo-MOF/NF) as a transducer for the detection of oral squamous cell carcinoma (OSCC). Herein, the interleukin-1 receptor antagonist (IL-1RA) antibody is used as a biorecognition element for the first time in the determination of oral cancer in real human blood samples using electrochemical impedance spectroscopy (EIS). Furthermore, the presence of specific functional groups ensures selectivity and rapid sensitivity against the target analyte IL-1RA when compared to the other biomarkers including interleukin-6 (IL-6), interleukin-8 (IL-8), CYFRA 21-1, and so on. The immunosensor shows a wide linear dynamic detection range of IL-1RA (10 fg/mL to 10 ng/mL) with a limit of detection (LOD) of 7.30 fg/mL in buffer and 7.22 fg/mL in serum conditions and a limit of quantification (LOQ) of 22.14 fg/mL in PBS and 21.88 fg/mL in serum. For a real-life demonstration, IL-1RA in human samples is detected by the immunosensor for the first time and compared with the gold standard method. The immunosensor also displays an excellent correlation with the standard detection of IL-1RA in human samples. Altogether, this work demonstrates that the electrochemical immunosensor has a high clinical significance by being a promising alternative to conventional approaches.

Nature-Inspired Surface Structures Design for Antimicrobial Applications

張家靖教授研究團隊發表研究成果於 Int. J. Mol. Sci.



Surface contamination by microorganisms such as viruses and bacteria may simultaneously aggravate the biofouling of surfaces and infection of wounds and promote cross-species transmission and the rapid evolution of microbes in emerging diseases. In addition, natural surface structures with unique anti-biofouling properties may be used as guide templates for the development of functional antimicrobial surfaces. Further, these structure-related antimicrobial surfaces can be categorized into microbicidal and anti-biofouling surfaces. This review introduces the recent advances

in the development of microbicidal and anti-biofouling surfaces inspired by natural structures and discusses the related antimicrobial mechanisms, surface topography design, material application, manufacturing techniques, and antimicrobial efficiencies.




112年1月16日上午10:30 於賢齊館310室邀請National Institute on Aging, NIH楊仁豪博士專題演講,講題為「Human skeletal muscle aging: Insights from myogenic RNA-binding factors」

本院有幸邀請National Institute on Aging, NIH楊仁豪博士於112年1月16日上午10:30於賢齊館310室進行演講,講題為「Human skeletal muscle aging: Insights from myogenic RNA-binding factors」,歡迎踴躍參與!

2023016 Special Seminar

國立陽明交通大學生物科技學院 111學年度第二學期逕行修讀博士學位開始辦理申請 【延長申請至112年1月9日】

 1.學業成績平均85分以上,具研究潛力者。
 2.名次在該班學生前10%以內,具研究潛力者。
 3.經系所評定為成績優異,具研究潛力者。
 (一)申請書
 (二)助理教授以上推薦函兩份以上,其中一份需由指導教授、系主任或所長推薦。
 (三)歷年成績單(含各學期名次證明)。
 (四)成果摘要(至多A4紙5頁)。
 (五) 研究計畫(至多A4紙5頁)。
 (一)審查佔50﹪